Active substance
Magnesium sulfate
- SFDA 5
- US FDA 23
- Health Canada 5
- WHO EML 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MAGNESIUM SULFATE 50% AMPOULE | 50 % | Solution for injection · Parenteral use | 1 Ampoule | SAR 4.20 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| MAGNESIUM SULFATE 50% I.V. Injection* | 50 % | Solution for injection · Parenteral use | 1 Vial | SAR 7.10 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| MAGNESIUM SULPHATE 10% Injection* | 10 % | Solution for injection · Parenteral use | 1 Vial | SAR 3.20 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| MAGNESIUM SULPHATE 10% Injection* | 10 % | Solution for injection · Parenteral use | 1 Vial | SAR 1.80 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| MAGNESIUM SULFATE 50% AMP | 50 % | Solution for injection · Parenteral use | 1 Ampoule | SAR 3.15 | Generic · Prescription | HOSPIRA INC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANESTHESIA-SUPPORTIVE AGENTS/ CARDIAC ARREST, CARDIOVASCULAR EMERGENCIES AND/OR DYSRHYTHMIAS; ARRHYTHMIA; ASTHMA; BURKITT`S LYMPHOMA; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); ESOPHAGEAL CANCER-RENAL TOXICITY; FOLLICULAR LYMPHOMA; GASTRIC CANCER-RENAL TOXICITY; HODGKIN'S LYMPHOMA; HYPOPARATHYROIDISM; MANTLE CELL LYMPHOMA; MATERNAL AND CHILD HEALTHCARE- PERINATAL,INTRAPARTUM AND POSTPARTUM CARE; MULTIPLE MYELOMA; NEONATAL RESPIRATORY DISTRESS SYNDROME (NRDS); T-CELL LYMPHOMA-RENAL TOXICITY; VENTRICULAR TACHYCARDIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MAGNESIUM SULFATE | 5GM/10ML (500MG/ML); 1GM/2ML (500MG/ML); 10GM/20ML (500MG/ML); 25GM/50ML (500MG/ML) | solution · intramuscular, intravenous | FRESENIUS KABI USA | Prescription | 8 Sep 1986 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 4GM/100ML (40MG/ML); 2GM/50ML (40MG/ML); 20GM/500ML (40MG/ML); 40GM/1000ML (40MG/ML) | injectable · injection | HOSPIRA | Prescription | 24 Jun 1994 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML; 2GM/100ML | injectable · injection | HOSPIRA | Prescription | 11 Jul 1995 |
| MAGNESIUM SULFATE | 5GM/10ML (500MG/ML) | solution · intramuscular, intravenous | HOSPIRA | Prescription | 25 Apr 2000 |
| MAGNESIUM SULFATE | 10GM/20ML (500MG/ML) | solution · intramuscular, intravenous | HOSPIRA | Prescription | 14 May 2015 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML | injectable · injection | HQ SPCLT PHARMA | Prescription | 2 Mar 2016 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML | injectable · injection | FRESENIUS KABI USA | Prescription | 7 Mar 2016 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 4GM/100ML (40MG/ML); 4GM/50ML (80MG/ML); 2GM/50ML (40MG/ML); 20GM/500ML (40MG/ML); 40GM/1000ML (40MG/ML) | injectable · injection | FRESENIUS KABI USA | Prescription | 15 Mar 2016 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML); 4GM/50ML (80MG/ML); 20GM/500ML (40MG/ML); 40GM/1000ML (40MG/ML) | injectable · injection | HQ SPCLT PHARMA | Prescription | 6 Dec 2017 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/50ML (80MG/ML); 4GM/100ML (40MG/ML) | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 1 Jun 2020 |
| MAGNESIUM SULFATE | 3GM/100ML (30MG/ML) | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 1 Jun 2020 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML) | injectable · injection | GLAND | Prescription | 10 Jul 2020 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML | injectable · injection | BAXTER HLTHCARE CORP | Prescription | 11 Aug 2020 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML | injectable · injection | B BRAUN MEDICAL | Prescription | 27 Oct 2020 |
| MAGNESIUM SULFATE | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML); 4GM/50ML (80MG/ML) | injectable · injection | B BRAUN MEDICAL | Prescription | 26 Apr 2021 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML); 4GM/50ML (80MG/ML) | injectable · injection | MILLA PHARMS | Prescription | 8 Nov 2021 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML) | injectable · injection | AMNEAL | Prescription | 15 Feb 2023 |
| MAGNESIUM SULFATE | 1GM/2ML (500MG/ML); 5GM/10ML (500MG/ML); 10GM/20ML (500MG/ML); 25GM/50ML (500MG/ML) | solution · intramuscular, intravenous | ASPIRO | Prescription | 28 May 2025 |
| MAGNESIUM SULFATE | 1GM/2ML (500MG/ML); 5GM/10ML (500MG/ML); 10GM/20ML (500MG/ML); 25GM/50ML (500MG/ML) | solution · intramuscular, intravenous | ADAPTIS | Prescription | 9 Jul 2026 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 4GM/50ML (80MG/ML) | injectable · injection | HOSPIRA | Discontinued | 24 Jun 1994 |
| MAGNESIUM SULFATE | 5GM/10ML (500MG/ML) | solution · intramuscular, intravenous | EXELA PHARMA | Discontinued | 18 Dec 2014 |
| MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER | 1GM/100ML | injectable · injection | PHARMOBEDIENT | Discontinued | 10 Sep 2018 |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | 2GM/50ML (40MG/ML); 4GM/100ML (40MG/ML) | injectable · injection | PHARMOBEDIENT | Discontinued | 14 Sep 2018 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MAGNESIUM SULFATE IN WATER FOR INJECTION | 02542153 | 40 MG / ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| MAGNESIUM SULFATE INJECTION USP | 00392618 | 200 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| MAGNESIUM SULFATE INJECTION USP | 02562235 | 500 MG / ML | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
| MAGNESIUM SULFATE INJECTION, BP 49.3% | 02513161 | 493 MG / ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| MAGNESIUM SULFATE INJECTION, USP | 02139499 | 500 MG / ML | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
WHO WHO Model List of Essential Medicines (2025)
- 5.1.1. Antiseizure medicines · core
Severe pre-eclampsia; Eclampsia
Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume) | Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
Safety signals and safety-related labeling changes
- US FDA 18 Nov 2025 SUPREP BOWEL PREP KIT — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Jul 2025 KABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Jul 2025 PERIKABIVEN IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 24 Oct 2023 SUTAB — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Patient Counseling Information / Patient Information / Medication Guide - MHRA 17 May 2019 Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
Maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy has been associated with skeletal adverse effects and hypocalcaemia and hypermagnesemia in neonates. If use of magnesium sulfate in pregnancy is prolonged or repeated, consider monitoring of neonates for abnormal calcium and magnesium levels and skeletal adverse effects.
Combinations containing Magnesium sulfate
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.